Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
May 14, 2007
- Shionogi Looks for Partner for Anti-Obesity Drug in PIII
May 14, 2007
- Safety of Crestor Confirmed in Japanese: AstraZeneca, Shionogi
May 14, 2007
- 5-Year Strategy to Develop Innovative Drugs, Med. Devices Proposed
May 14, 2007
- R&D NEWS IN BRIEF
May 14, 2007
- JSMI Announces 70 Candidates for Switch OTC Drugs
May 14, 2007
- Banyu Committed to Simultaneous Global Development
May 14, 2007
- Nihon Medi-Physics Completes Nationwide Distribution System for FDG
May 14, 2007
- GENERIC NEWS IN BRIEF
May 14, 2007
- Given Imaging to Launch Capsule Endoscope
May 14, 2007
- Kyowa Hakko Submits NDA for KW-6002 Combination Therapy for Parkinson's Disease in US
May 14, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 14, 2007
- Sales of Nicotinell Show 2.5-Fold Increase: Novartis
May 14, 2007
- Crestor, Drug of Choice for High-Risk Patients: Prof. Teramoto
May 14, 2007
- Amgen K.K. to Create Independent Development, Marketing Systems
May 14, 2007
- Tokyo Municipal Hospitals Share Criteria for Selection of Generics
May 14, 2007
- 6 Tokyo Prefectural Hospitals to Reduce Number of Drugs Used
May 14, 2007
- Towa Creates New Division to More Promptly Supply Information Required by Users
May 14, 2007
- BUSINESS NEWS IN BRIEF
May 14, 2007
- DSP Aims at Annual Sales of \170 Mil. Per MR in FY2009
May 14, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…